Previous Close | 0.5350 |
Open | 0.5110 |
Bid | 0.4843 x 100 |
Ask | 0.5658 x 100 |
Day's Range | 0.5100 - 0.5512 |
52 Week Range | 0.3720 - 40.3920 |
Volume | |
Avg. Volume | 251,611 |
Market Cap | 3.778M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -11.0000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 3.00 |
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. Click here to view the presentation. The new presentation, available
TARRYTOWN, NY / ACCESSWIRE / December 6, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, announced the release of a Fireside Chat video featuring Howard Weisman, Chairman ...
TARRYTOWN, NY / ACCESSWIRE / November 22, 2023 / PaxMedica, Inc. (NASDAQ:PXMD) ("PaxMedica" or the "Company"), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the closing of its previously announced ...